A 35-year-old woman with a 9-year history of Grave's disease delivered a male infant weighing 2,210 g at 32 weeks of gestation by caesarean section. The neonate developed thyrotoxicosis and, at the age of 24 h, was treated with oral carbimazole (500 µg every 8 h) and propranolol (2 mg/kg/day in two divided doses). He subsequently developed hypertension on day 4, which required therapy with amlodipine (0.1 mg once daily). Severe hypotension developed within 24 h and required discontinuation of amlodipine, with initiation of intravenous inotropic support with dopamine and dobutamine (at a rate of 20 µg/kg/min). The blood pressure rapidly normalized, and both dopamine and dobutamine infusions were stopped within 36 h. A Naranjo assessment score of 6 was calculated, indicating that the severe hypotension was a probable adverse drug reaction caused by the combination of amlodipine and propranolol therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982473PMC
http://dx.doi.org/10.1007/s40800-015-0004-6DOI Listing

Publication Analysis

Top Keywords

severe hypotension
12
dopamine dobutamine
8
amlodipine
4
hypotension amlodipine
4
amlodipine hypertension
4
hypertension newborn
4
newborn beta
4
beta blocker
4
blocker therapy
4
therapy thyrotoxicosis
4

Similar Publications

Dabie bandavirus and Mycoplasma pneumoniae co-infection: a case report.

BMC Infect Dis

January 2025

Jiangxi Medical Center for Critical Public Health Events, Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No.17 Yongwai Street, Donghu District, Nanchang, 330006, Jiangxi Province, China.

Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by Dabie bandavirus (DBV). We report a case of DBV and Mycoplasma pneumoniae (MP) co-infection.

Case Presentation: Here we reported a 57-year-old healthy male who was admitted with the presentations of fever, cough, hemoptysis, and hypotension.

View Article and Find Full Text PDF

Mechanism of syncope: role of ambulatory blood pressure monitoring and cardiovascular autonomic function assessment.

Eur Heart J

December 2024

Department of Cardiology, IRCCS Istituto Auxologico Italiano, Faint and Fall Research Centre, S. Luca Hospital, Piazzale Brescia 20, Milano 20149, Italy.

Background And Aims: Identifying the haemodynamic mechanism of autonomic syncope is the essential pre-requisite for effective and personalized therapy aimed at preventing recurrences. The present study assessed the diagnostic efficacy of a two-step assessment.

Methods: Multicentre prospective, cross-sectional, observational study.

View Article and Find Full Text PDF

The main treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is radical surgery, pulmonary thromboendarterectomy (PEA). However, about 40% of patients with CTEPH are inoperable due to distal pulmonary vascular lesions or the severity of hemodynamic disorders. Almost 30% of patients with CTEPH experience persistent or recurrent pulmonary hypertension after surgery, that requires a drug treatment with PAH-specific drugs.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Russian Medical Academy of Continuous Professional Education, Moscow, Moscow, Russian Federation.

Background: White matter hyperintensity (WMH), which is considered a sign of vascular lesions, is often found in patients with DLB, but its association with vascular lesions has not been proven. We assessed WMH in patients with DLB and markers of vascular damage and vascular risk factors.

Method: We examined 78 patients that fulfilled clinical criteria of DLB.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

BioXcel Therapeutics, New Haven, CT, USA.

Background: BXCL501, a sublingual film formulation of dexmedetomidine, a highly selective α2 adrenoceptor agonist, is currently being studied for the acute treatment of agitation associated with dementia.

Method: This was a Phase 1b/2 study assessing efficacy and tolerability of BXCL501 for treatment of acute agitation associated with dementia. Subjects were randomized to active treatment with BXCL501 (30, 40, or 60µg) or placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!